摘要
目的:探讨文拉法辛联合阿立哌唑与联合奥氮平治疗抑郁症的临床疗效和安全性。方法将62例抑郁症患者随机分为A组30例,B组32例,两组均口服文拉法辛治疗,A组联合阿立哌唑治疗,B组联合奥氮平治疗,观察6周。于治疗前后采用汉密顿抑郁量表评定疗效,副反应量表评定不良反应。结果治疗6周末 A 组显效率82.1%、有效率96.4%,B组分别为80.6%、96.8%,两组比较差异均无显著性(χ^2=0.02、0.00,P>0.05)。两组不良反应较轻微,发生率比较差异无显著性(P>0.05)。结论文拉法辛联合阿立哌唑与联合奥氮平治疗抑郁症均可快速起效,且疗效显著,总体疗效相当,安全性高。
Objective To explore the efficacy and safety of venlafaxine plus aripiprazole or olanzapine in the treatment of depression .Methods Sixty-two depression patients were randomly divided into group A (n=30) and B (n=32) ,both groups took orally venlafaxine ,group A was plus aripiprazole ,and B olanzapine for 6 weeks .Clinical efficacies were assessed with the Hamilton Depression Scale (HAMD) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) before and after treatment .Results At the end of the 6th week obvious effective and effective rate were respectively 82 .1% and 96 .4% in group A and 80 .6% and 96 .8% in B ,which showed no significant differences (χ^2 =0 .02 ,0 .00 ;P〉0 .05) .Adverse reactions of both groups were mild and their incidences had no significant group differences (P〉0 .05) .Conclusion Venlafaxine plus aripiprazole or olanzapine both takes effect rapidly ,has an evident effect and high safety ,and their total efficacy are equivalent in depression .
出处
《临床心身疾病杂志》
CAS
2014年第4期19-20,26,共3页
Journal of Clinical Psychosomatic Diseases